EMBL spin-off Epitome Therapeutics launches to advance precision epigenome editing
Epitome Therapeutics, a new EMBL spin-off, translates epigenome editing research into precision medicines. Co-founded by EMBL group leader Jamie Hackett, the company builds on pioneering research from EMBL Rome to open new possibilities for treating diseases caused by dysregulated gene expression.
SCIENCE & TECHNOLOGY2026
science-technology